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Available online 28 February 2006Valproic acid (VPA), a histone deacetylase inhibitor, causes differentiation in different cell
lines and in a cell-specific manner; yet, its effect onmegakaryocytic (MK) differentiation has
not been studied. We evaluated whether VPA induces MK differentiation in a UT-7 cell line
through histone acetylation in the GpIIIa gene region and activation of the ERK pathway. UT-
7 cells, derived from megakaryoblastic leukemia, were treated with VPA at various
concentrations, and the expression of differentiation markers as well as the gene
expression profile was assessed. Flow cytometry, immunoblot analysis, and RT-PCR
demonstrated that VPA induced the expression of the early MK markers GpIIIa (CD61)
and GpIIb/IIIa (CD41) in a dose-dependent manner. The VPA-treated cells showed
hyperacetylation of the histones H3 and H4; in particular, histone acetylation was
found to have been associated with CD61 expression, in that the GpIIIa promoter showed
H4 hyperacetylation, as demonstrated by the chromatin immunoprecipitation assay.
Furthermore, activation of the ERK pathway was involved in VPA-mediated CD61/CD41
expression and in cell adhesion, as demonstrated by using the MEK/ERK inhibitor U0126.
In conclusion, the capacity of VPA to commit UT-7 cells to MK differentiation is mediated
by its inhibitory action on HDAC and the long-lived activation of ERK1/2.
© 2006 Elsevier Inc. All rights reserved.Keywords:
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Histone acetylation [1] by histone acetyltransferase (HAT)
promotes transcription, facilitating the binding of transcrip-
tion factors to gene promoters [2]. Histone deacetylases
(HDAC) reverse chromatin acetylation and promote tran-
scriptional repression and silencing [2,3], whereas HDAC
inhibitors (HDACis) enhance the transcriptional activity of.
mpaolo).
work.
er Inc. All rights reservedseveral genes [4,5]. Currently known HDACis [i.e., sodium
butyrate (NaB) and trichostatin A (TSA)] cause changes in the
cell cycle, differentiation, and apoptosis, and they stimulate
adhesion molecules in different hematopoietic cell lines and
in a cell-type specific manner [6–8]. Recent data suggest that
valproic acid (VPA), a short chain fatty acid with a known
anticonvulsant and mood-stabilizing action, also inhibits
HDAC [4,5]. VPA suppresses cell growth in several cell lines.
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It also induces differentiation in transformed hematopoietic
progenitor cells and in blasts from persons with acute
myeloid leukemia [4]. In U937 and K562 cells, VPA induces
persistent acetylation of the histones H3 and H4 and
increases the transcription of endogenous genes, which is
strongly correlated with the induction of differentiation in a
myeloid- and erythroid-specific manner [9]. No data on
megakaryocyte (MK) differentiation are available.
Gene expression induced by VPA has been reported to
involve the activation of the extracellular signal-regulated
kinase (ERK) pathway [10]. ERK1 and ERK2 are members of the
mitogen-activated protein kinase (MAPK) family, which also
comprises the stress-activated protein kinase p38 and N-
terminal Jun kinases (JNK) [11]. Phosphorylated MAPKs have
been implicated as key regulators of specific responses [12–14].
The activation of ERK1/2 is critical for MK differentiation: the
inhibition of the MAPK-activating enzymes (MEK)/ERK path-
way has been found to alter polyploidization or to delay MK
maturation [15–18], whereas p38 activation is involved in
erythroid differentiation [19].
The human UT-7 cell line, which derives from megakaryo-
blastic leukemia [20], can be induced to differentiate along the
MK pathway by phorbol myristic acetate (PMA), with the
appearance of mature MK properties and the expression of
specific proteins such as platelet factor 4 and β-thromboglo-
bulin [20]. The objective of the present study was to determine
whether VPA induces MK gene expression in a UT-7 cell line
through the inhibition of HDACs and the activation of the ERK
pathway.Materials and methods
Antibodies and reagents
The following antibodies were used: anti-phospho p38 (New
England Biolabs, NEB, Beverly, MA), -CD61 (-integrin β3,
-GpIIIa), -ERK2, and -p38 (Santa Cruz, CA) polyclonal anti-
bodies; anti-phospho ERK1/2, -α-tubulin (Santa Cruz, CA), and
-gelsolin (Sigma, St. Louis, MO) monoclonal antibodies; PE-
conjugated CD41 (Immunotech, Marseille, France); and FITC-
conjugated CD61 (Becton Dickinson, San José, CA). Antibodies
recognizing the histones H3 and H4 and their anti-acetylated
forms were provided by Upstate Biotechnology Inc. (Lake
Placid, NY). VPA, NaB, and TSA were provided by Sigma, VPD
by Lancaster Synthesis (Morecambe, UK), and the MEK/ERK
pathway inhibitor U0126 by Promega (Madison, WI).
Cell culture and treatments
The UT-7 cell line [20] was cultured in liquid culture with
Iscove's modified Dulbecco's medium (IMDM; GIBCO Labora-
tories, Grand Island, NY) containing 10% fetal calf serum (FCS;
Hyclone) and 2 ng/ml of recombinant human GM-CSF (Pepro
Tech EC, London, UK). The cells were seeded at a density of
5 × 104/ml and cultured for 3 days in the presence or absence of
VPA (0.1, 0.25, 0.5, and 1.0 mM). Cultures with one of two
HDACis (i.e., 6 ng/ml TSA or 1.0 mM NaB) were also performed
for 3 days.Total and nuclear acid extracts
Floating cells were pelleted and suspended in lysis buffer [2%
sodium dodecyl sulphate (SDS) containing 2 mM phenyl-
sulphonyl-fluoride (PMSF), 10 μg/ml antipain, leupeptin and
trypsin inhibitor; 10 mM sodium fluoride; and 1 mM sodium
orthovanadate]. Adherent cells were harvested directly in lysis
buffer. The whole-cell lysates were sonicated for 30 s.
For nuclear acid extracts, 2 × 106 cells/sample were
suspended in 500 μl of ice-cold lysis buffer (10 mM Tris–HCl
pH 6.5, 50mM sodium bisulfite, 1% Triton X-100, 10mMMgCl2,
8.6% sucrose) containing the protease and the phosphatase
inhibitors. The nuclei were obtained after Dounce homogeni-
zation, and the acid-soluble histone fraction was extracted
according to the procedure of Yoshida et al. [6].
Immunoblot analysis
Proteins of total lysates and nuclear acid extracts were
measured [21], and equal amounts were separated by 10%
and 15% SDS-PAGE, respectively. The proteins were trans-
ferred to a nitrocellulose membrane (Schleicher and Schuell
BioScience GmbH, Germany) by electroblotting. The quantity
of total protein levels was confirmed by staining the mem-
branes with Ponceau S.
The antibodies for immunoblots were diluted according
to the manufacturer's recommendations, and incubation
with primary antibodies was carried out overnight at 4°C.
After 1.5 h of incubation with peroxidase-conjugated sec-
ondary antibody at room temperature, immunoreactive
bands were detected by chemiluminescence combined with
peroxidase activity (Product no. 34075, Pierce, Rockford, IL,
USA). The immunoblots were quantified by densitometric
scanning of the film using the Imaging Densitometer GS-700
(Bio-Rad, Hercules, CA, USA).
Flow cytometric analysis
The UT-7 cells were washed twice in PBS supplemented with
0.1% bovine serum albumin (Sigma) and incubated for 30 min
with fluorescent dye-conjugated CD41 and CD61 monoclonal
antibodies. After washing with PBS, the cells were analyzed.
The analysis of the UT-7 cell cycle was performed after 3
days of VPA treatment, incubating the cells in 10 μM bromo-
deoxyuridine (BrdU) for 30 min and then using the in situ
proliferation kit FLUOS (Roche, Basel, Switzerland). For the
bivariate analysis, the BrdU-labeled cells were counterstained
with 1 μg/ml of propidium iodide (PI) (Becton Dickinson).
Viable cells were determined by propidium iodide exclu-
sion test.
FACScan flow cytometer and Cell Quest software (Becton
Dickinson) were used.
RT-PCR analysis
Total RNA and reverse-transcribed-RNA were prepared as
described elsewhere [22]. cDNAs were equalized by RT-PCR
using primers for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Amplification consisted of denaturation at 95°C for
45 s, annealing for 45 s (at the temperatures specified below),
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temperatures, and PCR product lengths were as follows:
GpIIIa: forward 5′-ATCGAGTTCCCAGTGAGT-3′, reverse 5′-
TACTGGTGAGCTTTCGCA-3′, probe 5′-GATGATTCGAA-
GAATTTCTCCATCCAAGTG- 3′ (54°C, 283 bp);
α-globin: forward 5′-GACAAGACCAACGTCAAGGCCGCC-3′,
reverse 5′-CAGGAACTTGTCCAGGGAGGC-3′, probe 5′-GC-
AAGAAGGTGGCCGACGCGCTGAC-3′ (62°C, 372 bp);
GAPDH: forward 5′-ACATCAAGAAGGTGGTGAAGCAGG-3′,
reverse 5′-CTCTTCCTCTTGTGCTCTTGCTGG-3′, probe 5′-
TGACTTCAACAGCGACACCCACTCCTCCAC-3′ (56°C, 282
bp).
PCR was performed using Taq-Gold polymerase (Perkin-
Elmer, provided by RocheMolecular System Inc., NJ), following
the manufacturer's instructions; 10 μl of each sample was
separated in a 2% agarose gel (BRL Life Technologies Ltd.,
Paisley, UK), transferred to a nitrocellulose filter (Schleicher
and Schuell) and hybridizedwith the specific γ32P-ATP-labeled
probe. Amock reaction was used for each RT-PCR experiment.
Densitometric analysis was performed using Instant Imager
(Packard, Canberra, Australia).
Chromatin Immunoprecipitation (ChIP) Assay
Cells were cultured for 24 h without VPA, with 1 mM VPA
(the concentration at which the greatest expression of
CD61 was observed) or with 6 ng/ml TSA. Formaldehyde
was added to the cells to a final concentration of 1%, and
the cells were incubated at 37°C for 10 min. Cells (2 × 106)
were collected, and ChIP assay was performed with an H4
acetyl-histone immunoprecipitation assay kit (Upstate Bio-
technology, Lake Placid, NY), following the manufacturer's
instructions.Fig. 1 – Dose-dependent VPA induction of the CD61 and CD41 exp
CD61 expression in UT-7 cells, untreated or treatedwith VPA (1.0
presented. (B) CD61 and CD41 expression in UT-7 cells after 3 da
results of flow cytometric analysis; histograms were the mean ±Immunoprecipitated DNAs were amplified by PCR with
primers specific for the GpIIIa and GAPDH promoters. GpIIIa
promoter: forward 5′-GCATTGACACTGCTGTTAA-3′, reverse
5′-GCTGAAGCGTCACTAGCAA-3′, probe 5′-AGGGGAGGTA-
GATGGAGCTTCAGCCTGA-3′ (53°C, 154 bp). GAPDH promoter:
forward 5′-GCTACTAGCGGTTTTACGGG-3′, reverse 5′-CGAA-
CAGGAGGAGCAGAGAG-3′, probe 5′-GCCTGCCGCCGCGCC-
CCCGG-3′ (59°C, 167 bp). As a control for DNA content, PCR
reactions were also performed on chromatin samples prior to
immunoprecipitation (input).Results
Histone acetylation of GpIIIa promoter in UT-7 cells induced by
VPA
According to the results of flow cytometry (performed after 3
days of VPA treatment), VPA induced the expression of the
early MK-markers GpIIIa (CD61) and GpIIb/IIIa (CD41) (Fig. 1A)
in a dose-dependent manner, with the greatest expression
observed for the 1.0 mM concentration (Fig. 1B).
The immunoblotting analysis of nuclear extracts from
VPA-treated UT-7 cells showed hyperacetylation of H3 and H4.
For both histones, acetylation was present at 6 h of treatment,
peaked at 24 h, and was retained at 3 days (Fig. 2A). To
determine whether or not histone acetylation was associated
with CD61 expression, we performed ChIP assay with an
antibody specific for acetylated H4. Associated genomic DNA
was then analyzed by PCR using primers specific for the
promoter region of the GpIIIa gene. The promoter region of
GpIIIa was more acetylated in the cells treated with VPA
compared to the untreated cells (Fig. 2B).
Regarding the effect of other HDACis on the expression of
MK differentiation markers, 1.0 mM NaB increased CD41 andression in UT-7 cells. (A) Flow cytometric analysis of CD41 and
mM); representative experiment of three independent ones is
ys of VPA treatment (0.25, 0.5, and 1.0 mM) according to the
SEM of three independent experiments.
Fig. 2 – Correlation of histone acetylation in the GpIIIa promoter with CD61 and CD41 expression in UT-7 cells treatedwith VPA.
(A) Immunoblot analysis of H3 and H4 for acetylation in untreated cells (control, C) and cells treated with 1 mM VPA, by
treatment time. Filters were reprobed with an antibody recognizing total H4 histone. Representative blots are shown; at least
three other experiments were performed, all of which demonstrated a similar pattern. (B) Acetylation of the GpIIIa promoter in
UT-7 cells treated with VPA, as shown by ChIP assay. Anti-acetylated histone H4 antibody was used to immunoprecipitate
soluble chromatins from untreated cells (control, C) and cells treated for 24 h with 1 mM VPA. The immunoprecipitated DNAs
(ChIP) as well as chromatin samples before immunoprecipitation (Input) were subjected to PCR using primers for GpIIIa and
GAPDH promoters. All PCR products were of the expected size (see Materials and methods). As negative control (no Ab),
immunoprecipitation reactionwas carried out in the absence of antibody. (C) CD41 and CD61 expression in untreated UT-7 cells
(control, C) and UT-7 cells treated with VPA (1 mM), NaB (1 mM), or TSA (6 ng/ml) according to the results of flow cytometric
analysis; histograms were the mean ± SEM of three independent experiments.
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with respect to the control), whereas 6 ng/ml TSA induced a
less marked increase (Fig. 2C). Valpromide VPD (a VPA
analogue with no HDACi activity) neither induced acetylation
nor showed effect on CD41 or CD61 expression (data not
shown).
Furthermore, we tested, in UT-7 cells, the ability of VPA to
induce the expression of gelsolin, an actin-binding protein
known to be a target of HDACis in human cancer cells. VPA as
well as NaB and TSA induced gelsolin expression although at
different levels. Notably, 1 mM VPD did not (Fig. 3).Fig. 3 – Immunoblot analysis of the gelsolin expression in
UT-7 cells treated with HDACis. Whole cell lysates from
untreated cells (control, C) and cells treated for 3 days with
VPA (1.0 mM), NaB (1.0 mM), TSA (6 ng/ml), or VPD (1.0 mM)
were analyzed by immunoblot using an anti-gelsolin
antibody; filters were reprobed with α-tubulin antibody.
Representative experiment of three independent ones is
presented.
Fig. 4 – Adhesion of UT-7 cells following VPA treatment for
3 days. (A) Phase contrast micrographs of cells, untreated or
treated with VPA (0.5 mM); (B) cell adhesion (expressed as
the percentage of total treated cells), by VPA concentration.
Histograms were the mean ± SEM of three independent
experiments.
Fig. 5 – FACS analysis to measure the percentage of untreated or VPA-treated UT-7 cells in G1, S, and G2/M phase. Cells treated
for 3 dayswith VPA (1.0mM)were distinct in adherent (+VPA-A) and non-adherent (+VPA-NA) cells. Representative experiment
of three independent ones is presented.
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On the third day of VPA treatment, the cells began to adhere to
the plate surface and develop an elongated shape (Fig. 4A). Cell
adhesion increased in a dose-dependent manner, reaching
47% of the total cells with 1.0 mM VPA (Fig. 4B). Same results
were obtained with 1 mM NaB, whereas no cell adhesion was
observed in TSA- and VPD-treated cells (not shown).Fig. 6 – CD61 expression in adherent and non-adherent UT-7
cells treated with VPA (1.0 mM for 3 days). (A) Flow cytometric
analysis of CD61 expression in adherent (A) and non-adherent
(NA) cells; representative experiment of three independent
ones is presented. (B) Immunoblot analysis of the GpIIIa
expression in UT-7 cells treated with VPA. Whole cell lysates
(100 μg) from untreated cells (control, C) and adherent (A) and
non-adherent (NA) cells treated with VPA were analyzed by
immunoblot using an anti-GpIIIa antibody; filters were
reprobed with α-tubulin antibody. Representative experiment
of three independent ones is presented.Proliferation was inhibited at 0.5 and 1.0 mM VPA, with a
decrease of about 20–30% in the total number of cells,
compared to the untreated cells without significant cell
toxicity as evaluated by propidium iodide exclusion; no cell
toxicity and inhibition of cell growth were observed after TSA
and VPD treatment (data not shown).
In the adherent cells, the cell cycle profile showed cell
accumulation in the G2/M phase (Fig. 5), although the cell cycle
was not blocked in this phase, in that all of the cells progressed
to the G1/S phase after treatment with 1 mM hydroxyurea (not
shown).
The adherent and non-adherent cells differed in terms of
thedistribution ofMKmarkers: CD61 andCD41were expressed
in 87.8 ± 4.8%and 85.6 ± 7.5%, respectively, of the adherent cells
and in 63.5 ± 11.1% and 59.5 ± 15.5% (mean ± SEM from three
separate experiments) of the non-adherent cells. A represen-
tative CD61 experiment is shown in Fig. 6A. Both immunoblot
(Fig. 6B) and PCR analysis (Fig. 7) showed that GpIIIa expression
was higher in adherent cells than in non-adherent cells.
That VPA induced MK gene expression in UT-7 cells was
also suggested by the observed down modulation of α globin
gene expression, which was similar to the pattern of down
modulation obtained in vitrowith phorbol ester, an inductor of
MK differentiation (Fig. 7). No modulation of α globin geneFig. 7 – RT-PCR analysis of the expression of GpIIIa and
α-globin transcripts in UT-7 cells untreated (control, C),
treated with VPA (1.0 mM; adherent, A; non-adherent, NA),
VPD (1.0 mM), and phorbol 12,13-dibutyrate (PDB). GAPDH
gene expression was used as a quantitative control. (*the
volume of the PDB sample for GpIIIa was 1/10 that of the PDB
sample for GAPDH). A representative experiment is shown.
The expression pattern of each gene was confirmed in two
other experiments.
Fig. 8 – Immunoblot analysis of phosphorylated ERK1/2
(ERK1/2-P) and phosphorylated p38 (p38-P) in UT-7 cells,
untreated (control, C) or treated for 3 days with VPA (1.0 mM),
NaB (1.0 mM), TSA (6 ng/ml), or VPD (1.0 mM). Adherent cells,
A; non-adherent cells, NA. The treated cells were harvested,
and 80 μg cell lysate was subjected to immunoblot analysis,
using specific antibody against phosphorylated ERK1/2; blots
were stripped and reprobed with antibody against
phosphorylated p38. The total ERK2 and p38 are also shown.
Representative experiment of three independent ones is
presented.
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(Fig. 7).
Enhancement of GpIIIa expression through the activation of
the ERK pathway
To investigate whether ERK pathway is also involved in the
mechanism by which VPA stimulates early differentiative MK
markers, we analyzed the level of phosphorylated-activatedFig. 9 – Effect of inhibition of the MEK/ERK pathway on CD41 exp
UT-7 cells. (A) Dot-plot analysis of CD41 expression in cells prein
(1 mM). The experiment was performed three times, with simila
preincubated with different concentrations of U0126 and treatedw
The experiment was performed three times, with similar results
(control, C) and cells preincubated (1 h) or not with U0126 (10 μM
Representative experiment of three independent ones is presentforms of ERK1/2. Immunoblot analysis showed that, in the
adherent cells, the levels of the phosphorylated forms of ERK1/
2 were enhanced after prolonged treatment (3 days) with 1.0
mM VPA. Similar results were obtained using NaB, whereas
there was no enhancement with TSA or VPD (Fig. 8). In
adherent VPA-treated cells, phosphorylated p38, which is
specific to the erythroid differentiation pathway, showed a
70% reduction; while in adherent NaB-treated cells, a 30%
decrease was observed (Fig. 8).
In UT-7 cells pretreated with 10 μM U0126 (an inhibitor of
the MEK/ERK pathway), the expression of both CD41 (Fig. 9A)
and CD61 (not shown) was strongly impaired in cells treated
with 1.0 mM VPA. Cell adhesion was also impaired (Fig. 9B). To
determine whether ERK signaling affects histone acetylation,
we performed immunoblotting analysis on nuclear extracts
fromVPA treatedUT-7 cells, in the presence of 10 μMU0126. H4
acetylation was present at 6 h and 24 h and retained at 3 days
(Fig. 9C).Discussion
MK differentiation in UT-7 cells is known to be induced by
phorbol esters [20] and the constitutive expression of the TPO
receptor Mpl [23]. The results of the present study show that
also VPA induces early MK differentiation in UT-7 cells.
Depending on differentiation stage, VPA increases pro-
liferation and cell renewal in normal hematopoietic stem
cells [24,25] or induces differentiation in leukemia blasts as
well as in cell line [4,9]. Clinical observations in epileptic
patients reported that prolonged VPA treatment can lead to
thrombocytopenia with megakaryocyte dysplasia or bone
marrow suppression with a decrease number of megaka-
ryocytes [26,27]. A recent in vitro study on hematopoieticression, cell adhesion, and acetylation in VPA-treated
cubated or not with U0126 (10 μM) and treated with VPA
r results. (B) Number of adherent and non-adherent cells
ith VPA. Each value represents themean ± SEM of triplicates.
. (C) Immunoblot analysis of H4 acetylation in untreated cells
) and treated with VPA (1 mM), by treatment time.
ed.
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VPA and cytokines, showed increased percentage of differ-
entiated cells, in particular of the megakaryocytic lineage
[25]. Our study is in line with the in vitro results of De Felice
and coworkers [25]. UT-7 differentiation induced by VPA
was associated with a slight decrease in cell growth,
probably due to the slow progress in reaching the G1/S
phase. On the other hand, the increased proportion of cells
in G2/M phase represents an aspect of the induction of MK
differentiation program.
VPA-induced differentiation has been attributed to the
inhibition of HDACs [4,5,28]. In our study, the up-regulation of
MK glycoprotein expression was found to be associated with
the hyperacetylation of the nucleosomal histones H3 and H4;
in particular, histone acetylation was found to have been
associated with CD61 expression, in that the GpIIIa promoter
showed H4 hyperacetylation. The other HDACis up-regulated
CD41 and CD61 expression, yet to different extents. NaB up-
regulated CD41 and CD61 expression to the same extent as
VPA, whereas TSA induced a less marked increase, probably
because of differences in chemical structure [29]. VPD, an
analogue of VPA that does not inhibit HDACs, failed to induce
MK differentiation. All of the HDACis induced the expression
of gelsolin, an actin binding protein which is found in normal
MKs and platelets [30] and whose expression has been related
to the reversion of malignant transformation in several cancer
cell lines [31–33]. The induction of gelsolin expression in UT-7
cells is a further indication that acetylation is involved in
committing this leukemic cell line to an MK differentiation
program.
Previous studies have provided evidence that ERK is the
pathway involved in MK differentiation [15–18]. In the
adherent VPA-treated UT-7 cells, we observed a sustained
increase in the phosphorylated levels of ERK1/2, and when
we blocked ERK activation with U0126, we did not detect up-
regulation of CD61 or CD41 expression or cell adhesion.
Furthermore, the specific differentiation program induced by
HDACis varies with cell type: for example, in K562 cells VPA
and NaB induce erythroid differentiation [9,34]. The simulta-
neous decrease in the phosphorylation levels of p38 after
VPA treatment suggests that the activation of ERK1/2 and p38
are mutually exclusive in UT-7 cells. These data are
consistent with those from other studies in which the
erythroid differentiation of K562 was associated with the
inhibition of the ERK pathway and the activation of p38
[34,35]. Our results demonstrate that ERK pathway activation
and HDAC inhibition are associated in VPA induced MK
differentiation, although the increase in histone acetylation
is independent on ERK signaling. ERK inhibition by U0126
impaired expression of MK glycoproteins demonstrating the
involvement of the ERK pathway in the VPA-induced MK
differentiation. When using TSA, the ERK pathway was not
activated, which may explain why the CD41 expression was
slight.
The capacity to induce gene expression may vary among
HDACis [8], perhaps reflecting different modes of action [4,36].
VPA has been shown to induce massive apoptosis in APLmice
through the concomitant activation of Fas and TRAIL,
members of the TNF superfamily [37], whereas TSA, which
upregulates Fas expression but not TRAIL, only has a pooreffect. That we did not observe ERK phosphorylation with TSA
is consistent with these observations.
In conclusion, the capacity of VPA to commit UT-7 cells to
MK differentiation is mediated by the long-lived activation of
ERK1/2, and it is associated to its inhibitory action on HDAC.Acknowledgment
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